Privi Speciality Chemicals posted robust FY26 results with revenue up 22% to ₹2,563.69 crore and profit after tax soaring 71% to ₹316.72 crore. The company outlined a '5K:1K' vision aiming for ₹5,000 crore revenue by FY30.
Privi Speciality Chemicals Delivers Robust FY26 Financial Performance
Revenue from operations ₹2,563.69 crore; Profit after Tax ₹316.72 crore. Reader Takeaway: Strong revenue growth and profit surge driven by capacity expansion and product development. Potential pressure from integration of proposed amalgamations. ## What just happened Privi Speciality Chemicals Limited announced its consolidated financial results for the fiscal year 2025-26. The company reported a significant 22.01% year-on-year increase in revenue from operations, reaching ₹2,563.69 crore. Profit After Tax (PAT) also saw a substantial rise of 71.58%, growing from ₹184.75 crore in FY 2024-25 to ₹316.72 crore in FY 2025-26. Earnings Per Share (EPS) grew from ₹47.30 to ₹81.08. ## Why this matters These results demonstrate the company's successful execution of its business strategy, supported by healthy demand and an improved product mix. The sustained EBITDA margins above 20% indicate a resilient business model. The growth signals a positive outlook for shareholders, with clear strategic plans for future expansion. ## The backstory Privi Speciality Chemicals has been focusing on expanding its manufacturing capabilities and product portfolio. The company has a strategy of backward integration and is a key player in the speciality chemicals sector. ## What changes now The company has unveiled an ambitious '5K:1K' vision, targeting ₹5,000 crore in revenue and ₹1,000 crore in EBITDA by FY 2029-30. This vision will be propelled by increasing manufacturing capacity from 48,000 MTPA to approximately 72,000 MTPA by September 2028. The firm is also expanding its speciality chemicals portfolio and commercializing new molecules. ## Risks to watch Potential risks include the successful integration of the proposed amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited, which aims to enhance operational efficiency and research capabilities. The execution of the phased capital expenditure program is also crucial. ## Peer comparison (No specific peer comparison data was provided in the filing.) ## Context metrics (time-bound) * FY 2025-26 Consolidated Revenue: ₹2,563.69 crore (up 22.01% YoY) * FY 2025-26 Consolidated PAT: ₹316.72 crore (up 71.58% YoY) * FY 2025-26 EPS: ₹81.08 (vs. ₹47.30 in FY 2024-25) * Capacity expansion target: ~72,000 MTPA by September 2028 * Long-term target (FY 2029-30): ₹5,000 crore revenue, ₹1,000 crore EBITDA ## What to track next Investors will be keen to monitor the progress of the capacity expansion projects and the successful completion of the proposed amalgamations. Tracking the company's ability to maintain its EBITDA margins and achieve its long-term '5K:1K' vision will be key.
